港股異動 | 酷派集團(02369.HK)大幅反彈22% CEO稱明年爭取虧轉盈
格隆匯12月9日丨酷派集團(02369.HK)今日股價大幅上漲,現升22.09%,報0.199港元,暫成交1533萬港元,最新總市值10.02億港元。近期公司股價持續下跌創下52周新低0.146港元。連日來股價開始反彈,三日累升34%。日前,酷派集團在北京召開全體員工大會,酷派集團CEO樑鋭表示:“截止2018年,公司還處於虧損,今年7月成功復牌後,每個月開始盈利,今年可以做到不虧損,明年爭取實現扭虧為盈。”受此影響,今日股價持續拉昇反彈。據悉,酷派未來還將持續探索細分市場的消費者需求,研發智能穿戴領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.